epi-cell 2 mg/ml injektioneste, liuos
stada arzneimittel ag - epirubicini hydrochloridum - injektioneste, liuos - 2 mg/ml - epirubisiini
epirubicin sanoswiss 2 mg/ml injektioneste, liuos
sanoswiss uab - epirubicin hydrochloride - injektioneste, liuos - 2 mg/ml - epirubisiini
bortezomib mylan 3.5 mg injektiokuiva-aine, liuosta varten
mylan hospital as - bortezomibum - injektiokuiva-aine, liuosta varten - 3.5 mg - bortetsomibi
bortezomib krka 1 mg injektiokuiva-aine, liuosta varten
krka, d.d., novo mesto - bortezomibum - injektiokuiva-aine, liuosta varten - 1 mg - bortetsomibi
ondansetron kalceks 2 mg/ml injektio-/infuusioneste, liuos
as kalceks - ondansetron hydrochloride dihydrate - injektio-/infuusioneste, liuos - 2 mg/ml - ondansetroni
ondansetron b. braun 2 mg/ml injektioneste, liuos
b. braun melsungen ag - ondansetron hydrochloride dihydrate - injektioneste, liuos - 2 mg/ml - ondansetroni
ondansetron fresenius kabi 2 mg/ml injektioneste, liuos
fresenius kabi ab - ondansetron hydrochloride dihydrate - injektioneste, liuos - 2 mg/ml - ondansetroni
trexan 25 mg/ml injektioneste, liuos, esitäytetty ruisku
orion corporation - methotrexate - injektioneste, liuos, esitäytetty ruisku - 25 mg/ml - metotreksaatti
veramacor 2.5 mg/ml injektio-/infuusioneste, liuos
macure pharma aps - verapamil hydrochloride - injektio-/infuusioneste, liuos - 2.5 mg/ml - verapamiili
celdoxome pegylated liposomal
yes pharmaceutical development services gmbh - doksorubisiinihydrokloridia - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastiset aineet - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).